This site contains promotional information intended only for healthcare professionals resident in the United Kingdom
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Adverse event reporting can be found at the bottom of the page
Menu
Close
At Pfizer, we’ve shown how we can move with urgency to deliver breakthroughs that have the potential to change patients’ lives. And now, we’re making significant investments to tackle cancer – one of the biggest health challenges of our lifetime.1
Our approach is multifaceted. Through our portfolio, pipeline and strategic partnerships, we aim to provide treatments to cancer patients so they may live longer and healthier lives.
Around one in two people in the UK will develop some form of cancer within their lifetime.2 At Pfizer Oncology, we are committed to advancing medicines wherever we believe we can make a difference in the lives of people living with cancer.
We have established a dedicated Oncology R&D organisation that will combine the nimbleness of a smaller, science and technology-focused biotech with the resources and scale of the Pfizer enterprise. As of May 2024, our Oncology pipeline has 54 programs in development and 26 new molecular entities.3
In addition to our pipeline, we currently have more than 25 approved medicines and biosimilars covering more than 40 indications.4 And, during our Seagen acquisition in December 2023, we acquired four-in-line medicines – further bolstering our Oncology portfolio.4
Learn more about our pipeline and areas of research.
Patients are now - more than ever - equipped, informed and empowered to define healthcare in their own terms. We recognise the importance of harnessing the power of patient experiences to understand what healthcare means to the individual.
In 2022 we launched our first Cancer Insights Panel, developed to gather the perspectives of people impacted by cancer and enable Pfizer Oncology to act on the issues most important to those affected by the disease.
In addition to our medicines, we are also supporting patients through innovative technologies, such as the free ByYourSideTM app, a digital support programme designed specifically to help people living with cancer, as well as their friends and family members. Download ByYourSideTM from the Apple App Store or get it on Google Play.
References
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or search
for MHRA Yellow Card in Google Play or Apple App Store
Adverse events should also be reported to Pfizer Medical Information on 01304 616161
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc
This website is brought to you by Pfizer Limited, a company registered in England
and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ
Copyright © 2025 Pfizer Limited. All rights reserved.
VAT registration number GB201048427
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-UNP-GBR-7812. January 2024.